Understanding Clinical Trial Engagement in Merkel Cell Carcinoma

This study is looking at why some people with Merkel cell carcinoma (a rare and aggressive skin cancer) join clinical trials and others don't, and what helps people stay in trials until the end. Researchers want to understand if certain factors make it harder for some groups of people to participate or complete trials. By collecting information from 500 participants, this study aims to find patterns that could help improve future clinical trials for Merkel cell carcinoma patients. You can join if you are 18 or older, have Merkel cell carcinoma, and can understand and sign the consent form. The study will measure how many patients decide to join a trial within 3 months and how many stay in a trial for 12 months.

Study design
This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to enroll 500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will look at how many patients remain in clinical research for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06039033

Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns

Not Yet Recruiting
Not specifiedAges 18+Observational
Power Life Sciences Inc.
~500 participants
Updated 2023-09-15 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients who decide to enroll in a Merkel cell carcinoma clinical research
Measured over 3 months
+1 more outcome measured
Merkel Cell Carcinoma

NCT06039033

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Power Life Sciences

    San Francisco, Californiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Michael B Gill · STUDY_DIRECTOR · Power Life Sciences Inc.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged ≥ 18 years old
Able to comprehend the investigational nature of the protocol and provide informed consent
Diagnosis of Merkel cell carcinoma

Exclusion

No diagnosis of Merkel cell carcinoma confirmed
Inability to perform regular electronic reporting
Patient does not understand, sign, and return consent form
  • Number of patients who decide to enroll in a Merkel cell carcinoma clinical research3 months
  • Rate of patients who remain in Merkel cell carcinoma clinical research to trial completion12 months